MOG-IgA as a Potential Marker of Germinal Center Activity
To the Editor Ayroza Galv ão Ribeiro Gomes and colleagues recently identified the presence of myelin oligodendrocyte glycoprotein (MOG)–reactive immunoglobulin A (IgA) in a small subset of patients with a range of demyelinating central nervous system syndromes, particularly in those with seronegative central nervous syste m demyelination in whom clinical attacks occurred after vaccination or infection. In addition to a potential direct immunopathogenic role, we propose that MOG-IgA may represent a valuable marker of germinal center-based immunoglobulin class-switching, with potential clinical implications. (Source: JAMA Neurology)
Source: JAMA Neurology - January 16, 2024 Category: Neurology Source Type: research

Neurologic Alternative Payment Models —Bridging the Gap
This Viewpoint discusses alternative payments models and the responsibilities of health care professionals. (Source: JAMA Neurology)
Source: JAMA Neurology - January 8, 2024 Category: Neurology Source Type: research

Argatroban in Patients With Acute Ischemic Stroke With Early Neurological Deterioration
This randomized clinical trial investigates if argatroban improves neurological function in patients with acute ischemic stroke who experience early neurological deterioration. (Source: JAMA Neurology)
Source: JAMA Neurology - January 8, 2024 Category: Neurology Source Type: research

Trigeminal Ganglionopathy on Brain MRI —A Rare Etiology
This case report describes a 56-year-old man with periorbital swelling and hyperpigmentation on the right side of the face and a hypopigmented patch on the anterior chest. (Source: JAMA Neurology)
Source: JAMA Neurology - January 8, 2024 Category: Neurology Source Type: research

The Case of Anticoagulation for Progressing Stroke
Most stroke neurologists of a certain age will recall being taught —or perhaps teaching—that the correct treatment for a patient with progressing stroke was to administer parenteral anticoagulation, typically intravenous heparin. This strategy had the advantage of being biologically plausible. Because stroke progression was most often due to clot progression, t hen anything anticlotting seemed intuitively sensible. Further support came from one of the first multicenter randomized clinical trials in vascular neurology. In 1961 and 1962, Fisher and Baker et al reported the results of a national cooperative study of antic...
Source: JAMA Neurology - January 8, 2024 Category: Neurology Source Type: research

Ophthalmoplegia With Isolated Extraocular Muscle Hypertrophy
A 60-year-old man is experiencing diplopia but no problems with visual acuity, pain, or other symptoms. A magnetic resonance image of the head shows abnormal thickening and T2 hyperintensity of the right lateral rectus muscle. What is your diagnosis? (Source: JAMA Neurology)
Source: JAMA Neurology - January 8, 2024 Category: Neurology Source Type: research

The Perils and Pitfalls of Global Engagement
This Viewpoint describes ways to improve global collaboration among neurologists. (Source: JAMA Neurology)
Source: JAMA Neurology - January 2, 2024 Category: Neurology Source Type: research

Thrombectomy With the pRESET vs Solitaire Stent Retrievers as First-Line Large Vessel Occlusion Stroke Treatment
This randomized clinical trial evaluates whether thrombectomy for large vessel occlusion stroke with the pRESET stent retriever is noninferior to treatment with the Solitaire stent retriever. (Source: JAMA Neurology)
Source: JAMA Neurology - January 2, 2024 Category: Neurology Source Type: research

Punctate Diffuse Cortex Signals in Creutzfeldt-Jakob Disease
This case report describes 2 patients with genetic Creutzfeldt-Jakob disease with atypical changes on diffusion-weighted imaging. (Source: JAMA Neurology)
Source: JAMA Neurology - January 2, 2024 Category: Neurology Source Type: research

Addition of Nonauthor Collaborators and a Supplement
This article has been corrected. (Source: JAMA Neurology)
Source: JAMA Neurology - January 2, 2024 Category: Neurology Source Type: research

JAMA Neurology
Mission Statement: The mission of JAMA Neurology is to publish and disseminate scientific information primarily important for physicians caring for people with neurologic disorders and for those interested in the structure and function of the normal and diseased human nervous system. The specific aims are to (1) publish timely original research, including clinical trials that will directly improve clinical neurologic care and that will inform efforts to improve neurological health and promote health care equity; (2) report translational research that is pertinent to the understanding of neurologic disease; (3) address topi...
Source: JAMA Neurology - January 1, 2024 Category: Neurology Source Type: research

Error in Table 4
This article has been corrected. (Source: JAMA Neurology)
Source: JAMA Neurology - January 1, 2024 Category: Neurology Source Type: research

Error in Key for Figure 3
In the Original Investigation titled “Plasma Biomarker Strategy for Selecting Patients With Alzheimer Disease for Antiamyloid Immunotherapies,” which was published Online First on December 4, 2023, the amyloid β–positive groups were labeled incorrectly in the key for Figure 3. The article was corrected online. (Source: JAMA Neurology)
Source: JAMA Neurology - January 1, 2024 Category: Neurology Source Type: research

Looking Beyond Syndrome-Based Criteria for Autoimmune Encephalitis
This Viewpoint discusses how neural antibody –based diagnostic criteria for autoimmune encephalitis would complement the syndrome-based diagnostic algorithm to improve sensitivity while maintaining high specificity. (Source: JAMA Neurology)
Source: JAMA Neurology - December 26, 2023 Category: Neurology Source Type: research

Risk Factors for Young-Onset Dementia in the UK Biobank
This cohort study examines factors that are associated with the incidence of young-onset dementia among UK Biobank participants. (Source: JAMA Neurology)
Source: JAMA Neurology - December 26, 2023 Category: Neurology Source Type: research